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Abstract
Diabetic foot ulcerations have been extensively 
reported as vascular complications of diabetes mellitus 
associated with a high degree of morbidity and 
mortality. Diabetic foot syndrome (DFS), as defined 
by the World Health Organization, is an “ulceration 
of the foot (distally from the ankle and including 
the ankle) associated with neuropathy and different 
grades of ischemia and infection”. Pathogenic events 
able to cause diabetic foot ulcers are multifactorial. 
Among the commonest causes of this pathogenic 
pathway it’s possible to consider peripheral neuropathy, 
foot deformity, abnormal foot pressures, abnormal joint 
mobility, trauma, peripheral artery disease. Several studies 
reported how diabetic patients show a higher mortality 
rate compared to patients without diabetes and in 
particular these studies under filled how cardiovascular 
mortality and morbidity is 2-4 times higher among 
patients affected by type 2 diabetes mellitus. This 
higher degree of cardiovascular morbidity has been 
explained as due to the observed higher prevalence 
of major cardiovascular risk factor, of asymptomatic 
findings of cardiovascular diseases, and of prevalence and 
incidence of cardiovascular and cerebrovascular events 
in diabetic patients with foot complications. In diabetes 
a fundamental pathogenic pathway of most of vascular 
complications has been reported as linked to a complex 
interplay of inflammatory, metabolic and procoagulant 
variables. These pathogenetic aspects have a direct 
interplay with an insulin resistance, subsequent obesity, 
diabetes, hypertension, prothrombotic state and blood 
lipid disorder. Involvement of inflammatory markers such 
as IL-6 plasma levels and resistin in diabetic subjects 
as reported by Tuttolomondo et al  confirmed the 
pathogenetic issue of the a “adipo-vascular” axis that 
may contribute to cardiovascular risk in patients with 
type 2 diabetes. This “adipo-vascular axis” in patients 
with type 2 diabetes has been reported as characterized 
by lower plasma levels of adiponectin and higher 
plasma levels of interleukin-6 thus linking foot ulcers 
pathogenesis to microvascular and inflammatory events. 
The purpose of this review is to highlight the immune 
inflammatory features of DFS and its possible role as a 
marker of cardiovascular risk in diabetes patients and to 
focus the management of major complications related to 
diabetes such as infections and peripheral arteriopathy.
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Core tip: An immune activation has been reported 
as important at several stages in the development 
of chronic wounds of diabetic foot syndrome (DFS). 
Immune-inflammatory up regulation may precede the 
incidence of DFS in the same way that it precedes 
some major cardiovascular diabetic complication 
such as coronary heart disease as reported by some 
studies that showed a significant negative correlation 
of adiponectin plasma levels with cardiovascular risk 
factors such as hypertension, dyslipidaemia and with 
previous cerebrovascular events such as previous 
transient ischemic  attack/stroke and new onset events 
thus underlining the role of hypo-adiponectinaemia as a 
cardiovascular predictive factor in DFS.
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INTRODUCTION
Diabetes is a disease of  metabolism clinically expressed 
by chronic hyperglycemia and blood lipid and protein 
disorders that have been extensively reported as linked to 
several complications that significantly impair the quality 
of  life. Among diabetic vascular complications, foot ulcers 
represents the first cause of  hospitalization in diabetics 
and a significant cause of  health care costs (more than 
20%-40% of  health care resources have been reported as 
related to diabetes-related foot care)[1,2].
According World Health Organization, its’ possible 
encompass all foot complications in the term diabetic 
foot syndrome (DFS) that has been defined as “ulceration 
of  the foot (distally from the ankle and including the 
ankle) associated with neuropathy and different grades of  
ischemia and infection”[3]. More than 80000 amputations 
directly related to diabetes have been registrated in the 
United States annually[4] and the majority (80%) of  these 
have been performed in patients with a previous foot 
ulceration[5]. These foot vascular complications represent 
a very common precursor event prior of  lower extremity 
amputation among persons with diabetes[6,7]. Thus it 
explains that the foot ulcerations are considered as 
significantly predictive of  morbidity, mortality, and disability.
It has been extimated that 15% of  patients with 
diabetes will develop a lower extremity complication in 
their life[8]. Some authors reported a 0.5% to 3% incidence 
of  diabetic foot ulcers[9], whereas foot ulcer prevalence, as 
reported by some population surveys, ranges from 2% to 
10%[9]. A retrospective cohort study conducted in United 
States and enrolling more than 8000 patients with type 1 
and type 2 diabetes showed that new cases of  DFS were 
5.8 % over an period of  3 years[10]. More than 15% of  
patients with DFS experienced a lower limb amputation 
and some authors reported that survival rate in patients 
that undertaken a lower limb amputation is significantly 
shorter and more than $ 2700 is the cost for a 2-year care 
of  a new-diagnosed foot ulcer.
Foot ulcers have a complex and multifactorial 
pathogenesis with several causes working together to create 
pathogenetic pathway linked to foot ulceration onset in 
diabetic patients. Pathogenetic events able to cause diabetic 
foot ulcers are multifactorial. Among the commonest 
causes of  these pathways it’s possible to consider some 
triggers such as peripheral neuropathy, foot deformity, 
abnormal foot pressures, abnormal joint mobility, trauma, 
peripheral artery disease (PAD).
Peripheral neuropathy represents the most important 
cause in the pathway that causes foot ulceration in 
diabetic patients. Diabetic peripheral neuropathy (DPN) 
significantly impairs nerve activity throughout the body 
and can affect autonomic, motor, and sensory functions[11]. 
In sensory involvement the impairment of  sensation that 
protects foot skin integrity makes the foot vulnerable 
to thraumatic damage caused by an excess of  pressure, 
mechanical or thermal injury.
As reported by a recent study, sensory neuropathy 
represents the most frequent event in the patogenetic axis 
that causes ulceration in diabetic patients[12]. Other forms 
of  neuropathy may also play a role in foot ulceration. 
Motor neuropathy impairs the balance of  biomechanical 
forces, alter the integrity of  foot anatomy by means foot 
deformities, impaired joint mobility and compromised 
loading of  the extremities. These pathogenetic events 
impair mechanical forces balance during walking and 
induce a reactive thickening of  skin (callus) and thus 
facilitating ischemic necrosis of  tissues nearest to callus 
and leading to loss of  skin and subcutaneous tissue 
integrity (breakdown) and to ulcers that represent the final 
step of  this pathogenetic way.
Also autonomic neuropathy has a role in ulcer 
pathogenesis causing impairment and texture changes of  
skin integrity thus predisposing dryness and fissuring and 
opening   potential entry for bacteria. 
Another disorder that contributes to the development 
of  foot ulcers is peripheral vascular disease that affects 
the blood vessels of  small and large size. Both macro- and 
microvascular diseases are believed to contribute to the 
consequences of  peripheral vascular disease, resulting in 
the inability of  the ischemic limb to heal itself  properly. 
PAD has an increased incidence and prevalence in 
subjects with diabetes in relation of  age and duration 
of  disease. Hypertension, smoke habit, and lipid blood 
disorders are frequent comorbidities in diabetes with a well 
demonstred role in PAD pathogenesis. Studies have shown 
that peripheral vascular disease develops at a younger age 
among patients with diabetes as compared to the general 
population[13]. Ankle-brachial index (ABI), that originates 
by comparation of  the systolic blood pressure at posterior 
tibial or dorsalis pedal level with brachial blood pressure, 
it’s widely used to diagnose and evaluate severity of  PAD. 
In patients with an ABI < 0.90, the relative risk has been 
63 January 18, 2015|Volume 6|Issue 1|WJO|www.wjgnet.com
Tuttolomondo A et al . Immune-inflammatory features of diabetic foot syndrome
reported to be 1.25 (95%CI: 1.05, 1.47) for developing an 
ulcer vs diabetic patients with a normal ABI[14]. Lower limb 
ischaemia due to proximal arterial occlusive atherosclerosis 
is an important cause able to predispose to ulceration in 
more than 30% of  cases[15]. Nevertheless a recent study 
reported that diabetic patients with PAD are more likely 
in comparison to non-diabetic subjects to have a distal 
occlusive arterial disease and an higher incidence of  
amputions and death related to cardiovascular causes[13].
An ischaemic diabetic foot appears as red, dry and 
with clinical findings suggestive of  peripheral neuropathy 
and it also is susceptible to pressure damage by footwear. 
Thus diabetic foot with ulceration is a complex problem 
resulting of  the interplay of  multiple pathogenetic noxae 
such as neuropathy, peripheral vascular disease, trauma and 
infections. Neuropathy and ischaemia may represent the first 
acting factors, most often together as neuroi-schaemia that 
is peripheral neuropathy and vascular disease in overlapping, 
whereas infection is mostly a super-infection.
It’s possible to classify a diabetic foot in a pathoph-
ysiological and clinical way in: ischemic diabetic foot, 
neuropathic ischemic foot and infected diabetic foot, but 
this type of  classification in clinical practice may appear 
too simple owing to the fact that it’s possible to distinguish 
more frequent mixed clinical variants called neuro-ischemic 
diabetic foot. All these clinical variants of  DFS have typical 
morphologic and clinical findings (Figures 1 and 2).
In this review, we will examine research articles with 
regard of  involvement of  immune-inflammatory markers 
in DFS and the role of  DFS as a possible marker of  
cardiovascular risk in diabetic subjects.
CARDIOVASCULAR MORBIDITY IN 
PATIENTS WITH DFS
Diabetic patients show a poorer survival rate compared 
to patients without diabetes. Cardiovascular mortality and 
morbidity rates in diabetics have been reported by several 
studies as 2-4 times higher than in non-diabetic subjects. 
Different studies also indicate that foot ulcers in diabetic 
patients are linked to a higher mortality[13-17]. Furthermore 
diabetic foot represents an independent risk factor of  
morbidity in diabetic patients with a twice mortality rate 
due to cardiovascular disease in diabetic subjects with foot 
ulceration compared to those without foot ulceration[16,17].
In a study conducted by Roper et al[18], these authors 
hypothesized that patients with type 2 diabetes mellitus with 
diabetic foot could have a poorer cardiovascular prophile 
with a higher prevalence of  sublinical cardiovascular 
damage and of  cardiovascular morbidity. Thus authors 
evaluated differences between subjects with type 2 diabetes 
mellitus with and without diabetic foot with regard of: (1) 
cardiovascular risk profile; (2) previous cardiovascular event 
prevalence; (3) frequency of  markers of  asymptomatic 
cardiovascular damage; and (4) new-onset vascular events 
incidence. They reported a higher prevalence of  major 
cardiovascular risk factor, of  asymptomatic markers of  
CVD, and a higher prevalence and incidence of  previous 
and new-onset cardiovascular events in diabetic patients 
with foot complications (Tables 1 and 2).
These findings go along with previous reports of  
higher degree of  cardiovascular morbidity and mortality 
in diabetic patients with amputations[19,20]. The main cause 
of  death in these patients was coronary artery disease 
(CAD)[19,20]. 
Another finding of  this study was the higher 
prevalence of  major cardiovascular risk factors such as 
hypercholesterolemia, LDL plasma levels > 130 mg/dL, 
hypertriglyceridemia, and microalbuminuria/proteinuria 
in patients with foot complications compared to diabetic 
patients without foot complications thus strengthening 
the issue that DFS in diabetic subjects act as a real and 
important cardiovascular risk marker. 
Authors also reported that patients with diabetic 
foot were more likely to have a cerebrovascular event 
[transient ischemic attack (TIA) and ischemic stroke] both 
on retrospective evaluation (previous TIA and ischemic 
stroke) and on prospective evaluation (new onset TIA 
and stroke on a 5 years follow up). The most prevalent 
subtypes of  stroke were lacunar and LAAS subtype 
(Tables 3 and 4). The higher frequency of  lacunar subtype 
could underline the possible pathogenetic importance 
of  cerebrovascular disease either atherosclerotic and 
microvessel disease in patients with diabetic foot. 
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Figure 1  Infected diabetic foot ulcer. Tuttolomondo et al[21], personal data.
Pts with diabetic 
foot (n  = 102) 
<
Pts without 
diabetic foot 
(n  = 123)
P
  CAD (%) 33 (32.3) 24 (19.5)        0.0043
  TIA (%) 15 (14.7)   9 (7.3)     < 0.0001
  Stroke (%) 18 (17.6) 11 (8.9) < 0.05
  Stroke toast subtypes
     LAAS   6 (33.3) 5 (45.4) 
     Lacunar 12 (66.6) 6 (54.5)
    CEI            0 0
  Diabetic retinopathy (%) 55 (53.9) 47 (38.2) < 0.0001
  Renal failure (%) 6 (5.8) 7 (5.6) NS
Table 1  Prevalence of previous cardiovascular events in 
patients with and without diabetic foot
Modified from Pinto et al [19]. CAD: Coronary artery disease; TIA: 
Transient ischemic attack; LAAS: Large artery atherosclerotic stroke; CEI: 
Cardioembolic.
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collection. It is still the only anomaly of  early diabetic 
kidney that has prognostic value statements. In fact, the 
appearance of  microalbuminuria in diabetic patients is a 
very important index for progression to overt proteinuria 
and overt nephropathy. It has been reported as a 
cardiovascular risk indicator in diabetic populations owing 
to the fact that microalbuminuria is linked to an increased 
risk for all-cause and cardiovascular mortality also PAD. In 
a recent study conducted by Tuttolomondo et al[21] authors 
reported a higher prevalence of  microalbuminuria in 
patients with diabetic foot. These authors also reported a 
significant positive correlation between microalbuminuria, 
and interleukin (IL)-6 and resistin serum levels (Tables 5-7).
HYPERTENSION 
Diabetes mellitus and hypertension are frequent comorbidity 
and they represent two important independent risk 
factors for atherosclerosis and its complications. Diabetic 
Furthermore cardiovascular risk profile linked to diabetic 
foot seems to be related to the effects of  each cardiovascular 
risk factor added up a neuropathy and vasculopathy clinical 
background[21,22], but another further explanation could be in 
the role of  microangiopathy as a pathogenetic background 
of  overall vascular risk. 
Another study has been conducted by Pinto et al[20] 
to analyze diabetic foot as a stroke risk marker in type 2 
diabetic patients. Authors enrolled 102 type 2 diabetes 
patients with diabetic foot and 123 diabetic patients 
without diabetic foot. These authors reported a higher 
prevalence of  previous cerebrovascular events and a higher 
incidence of  new-onset strokes in patients with diabetic 
foot. They also reported a higher frequency of  lacunar 
and large artery atherosclerosis subtype thus confirming 
previous findings by the same group of  a worse stroke 
risk profile in diabetic patients with diabetic foot than in 
diabetic subjects without foot ulceration.
ROLE OF CARDIOVASCULAR RISK 
FACTORS
Microalbuminuria 
Microalbuminuria is defined by the detection of  urinary 
albumin excretion rates of  30 to 300 mg in a 24-h urine 
Figure 2  Diabetic foot ulcer. A: Neuroischemic diabetic foot ulcer; B: Neuropathic diabetic foot ulcer; C: Neuroischemic diabetic foot ulcer. Tuttolomondo et al[21], personal data.
A B C
Pts with diabeticfoot 
(n  = 102)
Pts without 
diabetic foot 
(n  = 123)
P
  CAD 12 (11.7)   7 (5.6) < 0.005
  Angina 4 (3.9)   3 (2.4) < 0.005
  Myocardialinfarction 8 (7.8)   4 (3.5) < 0.001
  TIA 6 (5.8)   4 (3.2)   < 0.0001
  Stroke 7 (6.8)   5 (4.0) < 0.005
  Renal failure 4 (3.9) 5 (4) NS
  Deaths 14 (13.7) 10 (8.1) < 0.005
  Cardiovascular cause 13 (12.7)   9 (7.3)
  AMI (3.9)     1 (0.81) NS
  Stroke 3 (2.9)   2 (1.6)
  CHF 3 (2.9)   3 (2.4)
  Other vascular cause 3 (2.9)   3 (2.4)
  Other cause 1 (0.9)     1 (0.81)
Table 2  Cox regression analysis of demographic and clinical 
variables associated with cardiovascular morbidity  n  (%)
From Pinto et al[19]. CAD: Coronary artery disease; TIA: Transient ischemic 
attack; AMI: Acute myocardial infarction; CHF: Congestive heart failure.
Diabetic foot 
(n  = 102)
No diabetic foot 
(n  = 123)
P
  TIA 15 (14.7)          9 (7.3) < 0.0001
  Ischemic stroke 18 (17.6) 11.8 (8.9) < 0.0001
  Stroke toast subtype:
     LAAS   6 (33.3) 5 (45.4) < 0005
     LAC 12 (66.6) 6 (54.5) < 0.005
     CEI            0          0
Table 3  Previous cerebro-vascular events in patients with and 
without diabetic foot
From Pinto et al[20]. TIA: Transient ischemic attack; LAAS: Large artery 
atherosclerotic stroke; LAC: Lacunar stroke; CEI: Cardioembolic.
Diabetic foot 
(n  = 102)
No diabetic foot 
(n  = 123)
P
  TIA 6 (5.8) 4 (3.2)   < 0.0001
  Ischemicstroke 7 (6.8) 5 (4.0) < 0.005
  LAAS             4              3 < 0.005
  LAC             3              2 < 0.005
  CEI             0              0 NS
Table 4  Incidence of stroke at follow-up in subjects with and 
without diabetic foot
From Pinto et al[20]. TIA: Transient ischemic attack; LAAS: Large artery 
atherosclerotic stroke; LAC: Lacunar stroke; CEI: Cardioembolic.
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nephropathy has been reported as the main factor that 
contributes to the development of  hypertension in patients 
with type 1 diabetes mellitus, whereas in patients with 
type 2 diabetes mellitus, hypertension is an expression 
of  insulin resistance and a clinical finding of  metabolic 
syndrome. Nevertheless, in both type 1 and type 2 diabetes, 
hypertension heavily influences prognosis and increase the 
risk of  macrovascular and microvascular complications. 
Hypertension increases the incidence rate of  diabetic 
retinopathy, nephropathy, and peripheral vascular disease. 
A study by Pinto et al[20] showed a similar prevalence of  
hypertension in both in patients with diabetic foot and 
those without it. In addition these authors showed a 
significant positive correlation between some clinical and 
laboratory variables such as serum levels of  IL-6 and 
resistin, adipocytokines involved in insulin resistance in the 
pathogenesis of  vascular inflammatory responses (Tables 
5-7).
DYSLIPIDEMIA
There are numerous cardiovascular diseases that occur 
in patients with diabetes, both type 1 or 2. Dyslipidemia 
in diabetics is strictly linked to cardiovascular disease 
pathogenesis. The defects in the synthesis and clereance 
of  plasma lipoproteins are among the most commonly 
metabolic abnormalities that accompany diabetes. The 
diabetic dyslipidemia, a characteristic pattern characterized 
by the presence of  low levels of  high density lipoprotein 
(HDL) cholesterol, hyper-tigliceridemia, and postprandial 
lipemia and that is observed more frequently in type 
2 diabetes, is one of  several factors that contribute to 
accelerating macrovascular disease in diabetic patients. 
Among the different factors involved in developing of  
diabetic dyslipidemia the following should be considered: 
insulin influences on apoprotein synthesis, regulation 
of  lipoprotein lipase, effect of  cholesteryl ester transfer 
protein, and adipose and muscle and peripheral insulin 
effects. The acknowledgment and treatment of  dyslipidemia 
are therefore two important elements in the framework of  a 
multidisciplinary approach aimed at the prevention of  CAD. 
However, considering the complexity of  the profiles of  
dyslipidemia in diabetic patients, multiple drugs are often 
required to achieve therapeutic targets. In addition, the 
other risk factors usually associated with diabetes mellitus, 
such as hypertension, hyperglycemia and obesity, should 
be effectively managed, to reinforce the effects of  lipid-
lowering therapy. Tuttolomondo et al[21] in a recent study 
reported a high frequency of  dyslipidemia in patients with 
diabetic foot ulcers than in those without diabetic foot also 
reporting a correlation between dyslipidemia and serum 
levels of  IL-6 and resistin indicating a possible role of  
inflammation pathogenetic markers on insulin resistance 
and its linked vascular damage (Tables 5-7). 
INFLAMMATION MARKERS IN PATIENTS 
WITH DFS
In diabetes, there is a complex interplay of  several inflam-
matory and metabolic aspects thus affecting cardio-
vascular system. Inflammation enhances insulin resistance, 
that is strictly linked to obesity, diabetes, hyper-tension, 
prothrombotic conditions and blood lipid disorders[23]. Some 
studies[22,24-26] suggested a possible interplay between some 
hormones, inflammatory cytokines and adipose markers 
such as resistin. Moreover, circulating levels of  adiponectin, 
an important adipocytokine, have been reported as reduced 
in obesity, type 2 diabetes and CAD[27-29]. This finding 
could explain how low serum level of  adiponectin were 
linked to low HDL-cholesterol (HDL-C) concentrations[30], 
low LDL particle size[28], and high serum levels of  markers 
of  inflammation[31]. Jeffcoate et al[32], reported that it’s 
possible to delineate a inflammatory cascade in diabetic 
foot pathogenesis as expressed by high serum levels of  
some inflammatory cytokines such as TNF-α and IL-1β. 
Although subclinical inflammation may represent 
a possible risk determinant of  type 2 diabetes and of  
its vascular complications, available data on diabetic 
neuropathies are poor. Thus some authors[33] analyzed 
the possible role of  serum levels of  some acute-phase 
Pts with 
diabeticfoot
Pts without 
diabetic foot
P
  n 34 37  0.75
  Age 66.7 ± 8.5 66.9 ± 7.9    0.027
  Sex male 16 (47.1)       15 (41.7)  0.41
  Diabetes duration
     < 10 yr   7 (20.6)       21 (58.3)   0.027
     = 10 yr   8 (23.5)        11 (30.6)   0.045
     = 20 yr 19 (55.9)         4 (11.1) < 0.001
  Treatment 
     Diet    4 (11.8 )        3 ( 8.3)   0.65
     Oral antidiabetics  3 (8.8 )       10 (27.8) < 0.001
     Mixed   6 (17.5)       13 (36,1) < 0.001
     Insulin  21 (61.8 )       10 (27.8) < 0.001
     Smoking   7 (20.6)      9 (25) 0.71
     Hypertension 20 (58.8)       25 (69.4)   0.041
     Dyslipidaemia 14 (41.2)       16 (44.4) 0.35
     Obesity 19 (55.9)       13 (36.1)   0.021
     Chronic renal failure 15 (44.1)        13 (36.1)   0.064
     Mycroalbuminuria 22 (64.7)         6 (14.7) < 0.001
     Retinopathty 19 (55.9)      36 (100) < 0.001
     PAD   10 (29.41)      9 (25)   0.54
     CAD      17 ( 50)       7 (19.4) < 0.001
     TIA/ Stroke   14 (41.17)            6 (16.66)     0.021
     Other district atherosclerosis  28 (82.35          21 (58.33) < 0.001
     Artropathy    11 (32.4%)           2 (5.6%) < 0.001
     Neuropathy   25 (73.52)             14 (38.88%) < 0.001
  Diabeticfootgrade
     Grade 0     1 (2.9%)
     Grade 1       6 (17.6%)
     Grade 2       8 (23.5%)
     Grade 3     10 (29.4%)
     Grade4       4 (11.8%)
     Grade 5     1 (2.9%)
     Grade 6       4 (11.8%)
Table 5  General and demographic variables in cases and 
controls  n  (%)
Data are expressed as median and interquartile (lower and upper quartile). 
Modified from Tuttolomondo et al[21]. PAD: Peripheral artery disease; 
CAD: Coronary artery disease. 
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proteins, cytokines, and chemokines. These authors 
evaluated 10 markers of  subclinical inflammation in more 
than 220 subjects with type 2 diabetic patients and diabetic 
neuropathy diagnosed by means the Michigan Neuropathy 
Screening Instrument (MNSI), showing that high levels of  
C-reactive protein (CRP) and IL-6 were most likely to be 
linked with diabetic polyneuropathy, high MNSI score, and 
specific neuropathic deficits, whereas an inverse relationship 
has been reported with regard of  IL-18. This study clearly 
reported that subclinical inflammation is associated with 
peripheral nervous system involvement in diabetics. 
Nevertheless, few data exist regarding the importance 
of  inflammation markers in patients with DFS. It has 
well demonstred how low-grade immune activation may 
represent an risk factor of  type 2 diabetes and for its 
vascular complications such as macrovascular (myocardial 
infarction and stroke) and microvascular ones (neuropathy 
and nephropathy). 
An immune activation has been reported as important 
at several stages in the development of  chronic wounds. 
Immune-inflammatory up regulation may precede the 
incidence of  a diabetic foot ulcer in the same way that it 
precedes some major cardiovascular diabetic complication 
such as CAD. Owing to the fact that pro- and anti-
inflammatory abnormalities could be important in 
different phase of  wound healing, it is suggestive that an 
immune-inflammatory impairment may damage tissue 
homeostasis and wound healing leading to the chronic 
wounds and realizing a complex clinical condition such as 
DFS. 
Weigelt et al[34] analyzed the possible relationship 
between foot ulcers and immune status in diabetic subjects 
with and without foot ulcers by evaluating some immune 
mediators. Authors reported how circulating levels of  
some inflammatory markers such as acute-phase proteins, 
cytokines, and chemokines were higher in patients with 
diabetic foot. Authors showed an higher degree of  serum 
levels of  CRP, fibrinogen, IL-6, macrophage migration 
inhibitory factor, macrophage inflammatory protein-1β, 
and interferon-γ-inducible protein-10.
However, since the existence of  a strict relationship 
between inflammatory and adypocite dysfunction marker, 
a possible interesting issue should be to evaluate the role 
of  adiponectin, resistin and inflammatory cytokines in 
patients with diabetic foot compared with those without 
foot complications.
A recent study by Tuttolomondo et al[21] has been 
conducted with this aim and  and authors analyzed serum 
levels of  adiponectin, resistin and IL-6 in subjects with 
diabetic foot in 34 patients with type 2 diabetes mellitus 
and foot ulceration and in control subjects with type 
2 diabetes mellitus without foot ulceration (Table 5). 
This study reported how diabetics with diabetic foot 
showed compared to diabetics without diabetic foot 
showed higher IL-6 and resistin plasma levels and lower 
adiponectin plasma levels (Table 6). Resistin, strictly 
involved in pathogenesis of  insulin resistance, may also 
have inflammatory interactions. A study[35] reported that 
lipopolysaccharide increased resistin expression in rat 
WAT, 3T3-L1 adipocytes and human monocytes. Studies 
conducted in animal models (murine) showed not univocal 
findings with regard a possible role of  pro-inflammatory 
cytokines as regulation factors of  resistin, nevertheless 
recent human studies reported and underlined a role 
Diabetic foot patients Diabetics without foot complications P
  HbA1c 8 (7.28-9.40) 6.85 (6.10-8.00) 0.018
  CRP 4 (2.25-5.15 ) 2.25 (1.90-3.08) 0.041
  Total cholesterol (mg/dL) 215.50 (166.50-243.00) 204.00 (185.50-210.00) 0.054
  LDL cholesterol (mg/dL) 121.70 (98.75-148.75) 104.50 (78.00-123.00) 0.032
  Tryglicerids (mg/dL) 160.50 (119.50-209.25) 180.50 (144.50-199.00) 0.012
  Globuli bianchi 12.675 (10775.00-14140.00 ) 10.700 (8850.00-12027.50) 0.032
  Adiponectin (µg/mL) 7.1450 (4.47-12.17) 8.480 (5.15-12.87) 0.022
  Resistin (ng/mL) 5.160 (2.96-6.29) 3.290 (2.37-6.5) 0.021
  IL-6 (pg/mL) 3.21 (1.23-5.34) 2.13 (1.24-3.97 ) 0.033
Table 6  Laboratory variables in cases and controls 
Demographic and anamnestic data are expressed as n° (percentage). Modified from Tuttolomondo et al[21]. HbA1c: Hemoglobin A1c; CRP: C-reactive 
protein; IL-6: Interleukin-6.
  Variable Adipenectin Resistin IL-6
R P  values R P  values
  Diabetes duration 0.36 (s) < 0.001 (s) 0.09 0.37
  Smoking 0.35 (s) < 0.001 (s) 0.1 0.22
  Hypertension 0.27 (s) < 0.05 (s) 0.12 0.35
  Dyslipidaemia 0.42 (s) < 0.001 (s) 0.14 0.15
  Obesity 0.13 0.42 0.12 0.22
  Chronicrenalfailure 0.11 0.56 0.12 0.35
  Mycroalbuminuria 0.08 0.37 0.08 0.37
  Retinopathty 0.1 0. 7 0.1 0. 7
  AOPC 0.11 0.81 0.1 0.77
  CHD 0.46 < 0.001 (s) 0.38 (s) < 0.0001 (s)
  TIA/stroke 0.12 0.42 0.13 0.32
  Other district 
  atherosclerosis
0.15
(s)
0.42 (s) 0.14 (s) 0.36 (s)
Table 7  Correlations of interleukin-1β, adiponectinresistin with 
clinical and laboratory variables in subjects with diabetic foot
Coefficients (R ) and P values are calculated by the Pearson correlation 
mode. Modified from Tuttolomondo et al[21]. s: Significative. CRP: 
C-reactive protein; TNF-α: Tumor necrosis factor-α; IL-1β: Interleukin-1β; 
IL-6: Interleukin-6; IL-10: Interleukin-10; ICAM-1: Intercellular adhesion 
molecule-1; V-CAM-1: Vascular cell adhesion molecule-1; vWF: Von 
willebrand factor; TPA: Tissue plasminogen activator; PAI-1: Plasminogen 
activator inhibitor-1. 
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of  inflammatory cytokine on resistin induction[36,37]. 
Osawa et al[38] reported how high serum resistin levels 
play as independent risk factor for ischemic stroke in a 
Japanese population also showing that high resistin serum 
levels associated with diabetes or hypertension furtherly 
increased cerebrovascular risk. Findings by Tuttolomondo 
et al[21] with regard of  higher plasma levels IL-6 plasma 
levels and resistin in diabetic subjects with foot ulceration 
in comparison with diabetics without foot complications 
seem to confirm this issue. 
Reilly et al[39] reported the role of  resistin as a metabolic 
mediator of  an interplay between inflammation and 
atherosclerosis. In contrast with resistin, adiponectin may 
inhibit resistin-mediated increase in vascular cell adhesion 
molecule 1 (VCAM-1) and intracellular adhesion molecule 
1 ( ICAM-1) serum levels[40,41]. 
Thus hypo-adiponectinemia can represent an early 
indicator of  a complex cardiovascular risk factor pattern 
predisposing to atherosclerosis and its organ-end damage 
complications as well as a contributing factor increasing 
progression of  the atherosclerotic plaque. 
Adiponectin has anti-inflammatory and athero-protective 
actions in various tissues by an inhibition action of  the 
expression of  vascular adhesion molecules and scavenger 
receptors, a reduction of  expression of  the inflammatory 
cytokine TNF-α, increasing of  NO production and 
lowering the proliferation and migration of  smooth muscle 
cells[42]. To date, two receptors mediate adiponectin’s actions 
in lipid and glucose metabolism such as ADIPOR1 and 
ADIPOR2[43]. Halvatsiotis et al[44] reported how a sequence 
variant in the intron 5 of  the ADIPOR2, rs767870 is more 
significantly associated with cardiovascular disease in a 
Greek population.
Findings by Tuttolomondo et al[23] of  lower median 
plasma levels of  adiponectin in subjects with diabetic 
foot seem to confirm this issue. Furthermore the same 
authors reported a significant negative correlation of  
adiponectin plasma levels with cardiovascular risk factors 
such as hypertension, dyslipidaemia and with previous 
cardiovascular events such as morbidity such as previous 
TIA/Stroke and new onset events such as neuropathy, 
micro- albuminuria thus further underlining the role 
of  hypo-adiponectinaemia as a predictive factor of  
cardiovascular events.
Adipose tissue has also inflammatory properties as 
expressed by cytokine production[45], thus it’s possible 
to hypothesize the existence of  an “adipo-vascular” 
axis[46], strictly involved in the pathogenesis of  increased 
cardiovascular risk in patients with type 2 diabetes. Findings 
such as lower degree of  serum adiponectin levels and 
and higher degree of  IL-6 serum levels may represent the 
pathogenetic and biological phenotype of  this “adipo-
vascular axis” in subjects with DFS involving both 
microvascular and inflammatory mechanisms. 
Some authors[47] analyzed adipocyte volume and its 
association with tumor necrosis factor alpha (TNF-α), 
IL-6, adiponectin and high sensitivity CRP (hs-CRP) 
levels showing how mean adipocyte volumes were higher 
in obese diabetic patients than in other groups. Authors 
also reported a significant positive correlation between 
adipocyte size and inflammatory markers, whereas a negative 
correlation has been reported between adipocyte size and 
adiponectin levels. These findings furtherly confirm the 
existence of  an adipose-inflammatory vascular axis strictly 
involved in diabetic complications such as DFS owing to the 
fact that adiposity and its related conditions, such as diabetes, 
are at the same time pro-inflammatory and inflamed 
conditions.
The evaluation of  association of  adipokines with the 
macrovascular complications of  type 1 diabetes mellitus 
(DM) was the aim of  a study[48] that analyzed serum 
adiponectin, leptin, and resistin levels in type 1 DM patients 
evaluating their association with carotid intima media 
thickness (CIMT). Authors showed how adiponectin is 
negatively correlated with CIMT, age, BMI, waist-to-hip 
ratio, and that exist a correlation between resistin and 
CIMT and systolic blood pressure. 
Indeed recent studies suggest that adiponectin may 
influence inflammatory vascular interactions by means 
a down-regulation of  adhesion molecules expression 
on endothelial cells[47], inhibition of  endothelial cell NF-
kB signaling[48], and lowering macrophage function[49,50]. 
Other studies showed how adiponectin can inhibit TNF-α 
mediated expression of  E-selectin, VCAM-1 and ICAM-1 
in human endothelial cells[47-49,51,52]. These findings furtherly 
confirm the vasoprotective action of  adiponectin45[53-60] and 
how this molecule may negatively modulate atherogenesis 
also by means its influence on inflammatory variables such 
as TNF-α. 
The pathophysiology of  insulin resistance and 
atherosclerosis share a common inflammatory basis. 
Thus some authors[59] to test this hypothesis, evaluated 40 
patients with a myocardial infarction [M]. Endothelium-
dependent flow-mediated dilation (FMD) and -independent 
nitroglycerine vasodilatation (determined by ultrasound), 
S(I) (insulin sensitivity index; determined by isoglycaemic-
hyperinsulinaemic clamp) and serum levels of  CRP, 
TNF-α, IL-6, resistin and adiponectin (determined by 
ELISA) were measured. FMD, S(I) and adiponectin levels 
resulted significantly lower in patients with T2DM, whereas 
TNF-α and IL-6 levels have been observed as significantly 
higher in patients with T2DM. Authors also reported that 
TNF-α concentrations and brachial artery diameter were 
negatively, whereas S(I) was positively, correlated with 
FMD. These results indicate how endothelium is negatively 
impacted in multiple ways by the diabetic state after an MI 
also suggesting endothelium as the main organ-target of  
adipose-inflammatory dysfunction of  diabetes. 
Furthermore, in a recent paper Zietz et al[49] reported 
an association between low levels of  adiponectin and 
low levels of  HDL-cholesterol and how this relationship 
seems to act as independent cardiovascular risk factor. The 
same authors also reported that high levels of  adiponectin 
are associated with high levels of  HDL-cholesterol thus 
suggesting how adyponectin can be involved in a so called 
“cardioprotective” pathway together with HDL levels. 
This findings could find a confirmation in results reported 
by Tuttolomondo et al[21] showing respectively a positive 
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(for IL-6 and resistin) and negative [for adiponectin] 
correlation in subjects with diabetic foot with regard of  
some metabolic markers and some clinical and laboratory 
variables. Recently DFS has been reported by Pinto et 
al[19] as a predictive factor of  cardiovascular morbidity in 
diabetic patients. 
Other research underlined the positive correlation 
between inflammatory cytokines and cardiovascular 
morbidity in diabetic patients. Tuttle et al[52] reported higher 
degree of  serum levels of  IL-6 and TNF-α in diabetic 
women with and without CVD compared to nondiabetic 
women thus suggesting a common inflammatory state in 
both diabetes and cardiovascular diseases. 
In diabetic foot have been described some abnorma-
lities such as an inflammatory state, low collagen levels 
due to low synthesis and higher degradation and these 
changes have an important role in impairment of  wound 
healing. Cathepsin D, an aspartic endopeptidase is able to 
reverse the inhibition of  collagen biosynthesis in wounded 
rat skin with diabetes. Some authors[54] reported how 
patients with diabetic foot ulcer have higher median 
plasma level of  Cathepsin D and lower median plasma 
levels of  adiponectin, also showing a positive correlation 
between variables such as ulcer severity, BMI, A1c and 
retinopathy and Cathepsin D and a negative correlation 
with adiponectin. Thus most of  research experiences seem 
to suggest that atherosclerosis in diabetes could be a real 
inflammatory disorder. A study[60] evaluated the prevalence 
of  inflammatory markers such as high-sensitivity CRP, 
adiponectin, and nuclear factor-κB (NF-κB) expression, in 
peripheral blood mononuclear cells in patients with type 2 
diabetes mellitus (T2DM) with and without macrovascular 
disease. Authors reported how diabetic subjects with 
T2DM showed a higher hsCRP and NF-κB expression 
and a lower degree of  adiponectin serum levels compared 
to healthy controls. 
INFECTIONS IN PATIENTS WITH DFS
Definition of  diabetic foot infections (Table 8) indicate 
infectious diabetic foot as a “clinical syndrome characterized 
by the presence of  local signs of  inflammation such as 
redness, warmth, induration, pain or tenderness and 
purulence, sometimes in the context of  a framework of  
sepsis, that occurs in a site below the malleoli in a person 
with diabetes”[61]. Infections on diabetic foot can represent 
a common and dangerous complication of  diabetes 
owing to the fact that they can involve deeper soft and 
bone tissuse (cellulitis and osteomyelitis) thus significantly 
increasing the risk of  amputation. 
Diabetes is the main cause of  non-traumatic amputation 
of  the lower limbs in the world. In a recent study[62,63] 
enrolling patients with DFS, infections increased the risk of  
a minor amputation by 50% compared to patients without 
infection. Among factors able to predispose to infections on 
diabetic foot it’s possible to include: foot ulcer duration of  
longer than 30 d, a history of  recurrent foot ulcers, traumatic 
causes, peripheral vascular disease and neuropathy.
Wound infections are polymicrobial including gram-
positive cocci (Staphylococcus aureus, β-streptococci, 
usually group B, or coagulase-negative staphylococci), Gram-
negative rods (e.g., Escherichia coli, Proteus, Klebsiella), 
sometimes including non-fermentative Gram-negatives (P. 
aeruginosa), and anaerobes (e.g., Finegoldia, Bacteroides).
Infectious Disease Society of  America (IDSA) 
guidelines indicate that infection on diabetic foot is present 
when there is purulent drainage and/or the presence of  
two or more signs of  inflammation[63]. Possible infection 
signs are: fever, chills, hypotension, anorexia, nausea, 
vomiting, change in mental status and hyperglycaemic state 
and blood abnormalities such as leukocytosis, elevated 
sedimentation rate, CRP or procalcitonin levels or positive 
blood cultures are further signs of  a severe infection. 
Nevertheless in more than 50% of  patients with diabetes 
and infectious DFS these signs were absent[64]. 
Different classification systems developed in the last 
years for the stadiation of  diabetic foot infections, but a 
widely accepted method is the IDSA classification scheme, 
with four progressive levels of  infection and with a good 
correlation with clinical findings[65,66].
The diabetic foot ulcers require an appropriate 
antimicrobial treatment preferably targeted on the basis 
of  microbiological culture and that includes agent active 
against gram positive cocci which are the most common 
pathogens. Surgical management is sometimes necessary.
PERIPHERAL ARTERIAL DISEASE AND 
DFS
Diabetic foot ulceration (DFU) with its high morbidity and 
mortality represents an important cause of  hospitalization in 
  Clinical description Infectious Diseases Society of America
  Wound without purulence or any manifestations of inflammation Uninfected
  ≥ 2 Manifestations of inflammation (purulence or erythema, pain, tenderness, warmth, or induration); anyc   
  ellulitis or erythemaextends 52 cm around ulcer, and infection is limited to skin or superficial subcutaneous   
  stissues; no localcomplications or systemic illness
Mild
  Infection in a patientwho is systemicallywell and metabolicall ystable buthas 2 cm; lymphangitis; spread   
  beneath fascia; deeptissue abscess; gangrene; muscle, tendon, joint, or bone involvement
Moderate
  Infection in a patient with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia,   
  hypotension, confusion, vomiting, leukocytosis, acidosis, hyperglycemia, or azotemia)
Severe
Table 8  Diabetic foot infection classification schemes: Infectious Diseases Society of America Infectious Diseases
Adapted from Lavery et al[67].
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diabetics and it is an independent risk factor for peripheral 
arterial disease. PAD, presents in half  of  patients with DFU, 
is a condition characterized by steno-obstructive lesions 
downstream of  the renal arteries that lead to a reduction 
in the perfusion of  the lower limbs and it represents a 
common cause of  impaired ambulation and is a leading 
cause of  lower extremity wounds and amputations[53,54]. In 
fact, diabetes mellitus which can be considered as a whole 
as an inflammatory disease is burdened with microvascular 
complications such as nephropathy, retinopathy and 
neuropathy and macrovascular complications including 
stroke, myocardial infarction (MI), and PAD that occur 
earlier than in nondiabetic patients and the underlying 
pathologies are often more diffuse and severe.
Microvascular and macrovascular complications of  
diabetes although they affect small vessels, and large 
vessels, have a similar pathogenetic background. Chronic 
hyperglycemia has a leading role in this pathogenetic pathway 
that leads to vascular complications by means either 
metabolic and structural abnormalities such as advanced 
glycation end products (AGE) production, activation of  
protein kinase C (PKC), high degree of  reactive oxygen 
species (ROS, oxygen-), and impairment hemodynamic 
regulation and activation of  the renin-angiotensin system 
(RAS).
Other pathogenetic factors are inflammation, coagul-
ation disorders, smooth muscle cell involvement, endothelial 
dysfunction, impairment of  blood supply and impairment 
of  platelet action.
Diabetic arteriopathy is characterized by changes 
in the arterial wall that include arterial narrowing with 
increased intima-media thickness. The first site of  injury 
is the vascular endothelium that is the central candidate 
barrier against atherogenesis process. Endothelium produces 
important substances such as nitric oxide (NO) that 
induces vasodilatation and also regulates platelet-vessel wall 
interaction, thereby functioning as an antiplatelet agent. 
The alterations that occur in diabetes such as chronic 
hyperglycemia and insulin resistance alter the endothelial 
production of  NO and impaired arterial vasodilation in 
diabetes. In addition to the reduction in the vasodilatory 
response in diabetes occurs overproduction of vasoconstrictor 
substances such as endothelin 1. This endothelial dysregulation 
causes structural and functional alterations that characterize 
the later diabetic arterial disease[67-69]. Another atherosclerotic 
pathogenetic background is an inflammatory activation. In 
fact, an increased expression of  adhesion molecules induces 
inflammatory cells cross endothelial barrier and reach into 
intima media of  the vessel wall and subsequent ingesting 
oxidized LDL and forming foam cells, an important 
component of  atherosclerotic fatty streaks that represent an 
early marker of  macrovascular disease.
Impairment in coagulation, fibrinolysis, and platelet 
action, represents the basis of  the thrombophilic state 
leading to increased risks for thrombogenesis, atherosclerosis 
progression, and plaque events which are involved in the 
development of  cardiovascular complications in diabetes. 
Age and duration of  diabetes are strictly related with 
frequency of  PAD in both diabetic and nondiabetic patients. 
Other risk factors such as hypertension, smoking, and blood 
lipid disorders have a high prevalence in diabetic subjects 
thus enhancing vascular risk. However, if  the supply of  
blood fails to satisfy ongoing metabolic requirements as a 
consequence of  arterial narrowing, symptoms will occur, 
the severity of  which depends on the degree of  arterial 
narrowing, number of  arteries affected, and the activity 
level of  the patients. PAD can present with pain of  one 
or more lower extremity muscle groups related to activity 
(intermittent claudication), atypical pain, pain at rest, or 
with nonhealing wounds, ulceration, or gangrene.
Clinical history and physical examination are essential 
to diagnose a condition of  PAD in a diabetic subject. 
Suggestive of  PAD diagnosis are a history of  intermittent 
claudication, coronary artery disease, cerebrovascular 
events, foot ulcers, angioplasty, or surgical bypass. 
Objective exam can help to determine the extent and 
distribution of  peripheral vascular disease[70,71] in diabetics, 
but measurement of  the ankle-brachial index (ABI) 
calculated as systolic blood pressure at posterior tibial or 
dorsalis pedal level compared with brachial blood pressure, 
is a useful method to evaluated an occlusive PAD. An ABI 
of  ≤ 0.90, is higly sensitive and specifical for a diagnosis 
of  PAD. To assess the severity of  the perfusion, the 
evaluation of  below-knee vessels is particularly important 
in patients with diabetes and duplex ultrasound is a first 
line investigation[72]. 
Multiple factors impair wound healing in diabetes 
in addition to PAD. Patients with mild PAD and ABI > 
0.6, should be initially managed with local wound care 
(debridement and treatment of  infection) and a period of  
observation. Extended ulcers and infected ulcers with a 
poor extended outcome a early vascular intervention may 
be required[73]. Revascularization is indicated for critical 
limb ischemia and for some patients with claudication. 
Surgical risks and the degree of  severity of  foot ulcers may 
influence the surgical therapeutic option vs endovascular 
intervention. Thus depending upon the characterization 
of  a given arterial lesion, a diabetic patient with PAD 
may benefit from a surgery-first or an angioplasty-first 
approach. Most diabetics with critical ischemia have 
popliteal/tibial site of  occlusion thus therapeutic option 
requires a surgical approach below-the-knee or bypass 
grafting[74]. 
A study conducted by Ciccone et al[75] evaluated the 
outcome of  patients with diabetic foot who underwent 
angioplasty (PTA) revascularization. Authors reported 
at 1 year follow-up, a “major”/”minor” events incidence 
of  15%. Authors also reported that obesity, high LDL 
levels and an arterial lesion at a distal site were statistically 
significantly associated with major events and how high 
levels of  inflammatory markers such as PCR had a 
significant relationship with the ulcer recurrence.
The results of  this study highlighted the fact that 
diabetic foot disease is an important social problem 
because of  the hight incidence in the population and the 
risk of  major and minor complications and therefore a 
rapid diagnosis and prompt revascularization treatment, 
if  needed, are essential to improve the quality of  live 
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and prolong survival. Nevertheless, other experimental 
therapeutic options could be useful in clinical setting of  
diabetic foot ulcerations. Clinical care of  patients with foot 
ulcers and infection is not easy and often it is required a 
revascularization treatment by surgical or endovascular 
approach. However, it is appropriate to consider novel 
therapeutic approaches such as extracorporeal shockwave 
(SW). Extracorporeal SW therapy could improve the 
natural course of  such a disease due to its action on the 
endothelium of  blood vessels to improve angiogenesis 
and ameliorate symptoms in patients with limb ischemia. 
A recent study conducted by Ciccone et al[76] analyzed the 
effects of  SW therapy in patients with PAD. In this study 
twenty-two patients were enrolled and were randomly 
assigned into two groups: SW treatment (12 patients, 67 ± 
9 years) and control (10 patients, 68 ± 12 years). Stenosis 
greater than 75% causing a hemodynamic impairment was 
treated with SW therapy. All patients underwent a Doppler 
ultrasound of  the lower limb arteries in their entirety and a 
clinical-functional evaluation of  their condition (e.g., ABI) 
before and after the treatment. Findings of  this study 
showed a significant improvement of  stenosis degree after 
treatment in patients treated with SW. 
In addition, a significantly higher number of  treated 
patients than controls showed a reduction in the Fontaine 
stage. On the basis of  these data, although studies in larger 
samples are needed to confirm the results of  this study, 
the authors hypothesized that SW therapy could represent 
a useful tool in PAD therapy, and may prepare patients for 
more aggressive therapy.
FOCUS ON NON ALCHOLIC FATTY LIVER 
DISEASE AND DIABETES
Non-alcoholic fatty liver disease (NAFLD) is a frequent 
comorbidity in diabetic subjects (type 2 diabetes mellitus) 
and in those with metabolic syndrome (MS), with a 
frequence of  more than 30%. NAFLD represents the 
hepatic organ damage related to MS that encompasses 
multiple cardiovascular risk factors and that recognize 
as central pathogenetic basis insulin resistance and as 
clinical expression several diseases such as visceral obesity, 
hypertension, blood lipid disorders and type 2 diabetes. 
The term NAFLD encompasses some hepatic disorders 
with the primary pathologic findings of  microvesicular 
hepatic steatosis that occurs without a clinical history of  
significant alcohol consumption. In this clinical setting 
context it has been distinguished a disease with histologic 
essential fat accumulation (steatosis) and a disease in 
which steatosis coexists with a state of  liver-cell injury and 
inflammation called non-alcoholic steatohepatitis (NASH). 
These two conditions show an increased prevalence and 
incidence thus becoming a real public health problem 
due to their strict relationship with diabetes and obesity 
pandemias. The pathogenesis of  NAFLD is not fully clear, 
but insulin resistance appears to be as the main pathogenetic 
metabolic event, even if  many other predisposing conditions 
such as obesity, oxidative stress, cytokine/adipokine axis 
have been reported as plausible coexisting pathogenetic[77].
Insulin resistance represents the clinical expression of  
the inability of  endogenous insulin to enhance glucose 
uptake and its utilization and it is the physiopathological 
main factor able to induce the metabolic syndrome. 
Insulin acts by means of  binding to its plasma membrane 
receptor and its effects are mediated by a series of  cellular 
messengers acting by mechanisms of  protein-protein 
interactions that have been reported as impaired by several 
factors such as increased levels of  fatty free acids (FFAs), 
oxidative damage, inflammation and abnormalities of  
cytokines/adipokines interplay able to induce a peripheral 
(muscle and adipose tissue) and hepatic insulin resistance. 
Insulin resistance enhances hepatic lipid accumulation thus 
increasing liver FFA influx and stimulating some enzymes 
involved in lipogenesis in liver and thus may be indicated 
as the typical physiopathological finding of  NAFLD[78]. 
Furthermore, visceral fat plays a central role in the 
pathogenesis of  insulin resistance and NAFLD owing to 
the fact that adipose tissue is not an inert tissue but it acts as 
a real active endocrine organ, thus furtherly impairing insulin 
resistance and influencing cytokine/adipokine pathways 
in terms of  increased levels of  FFA, adiponectin, leptin, 
TNF-α, IL-6. In particular adiponectin acts as a leading 
mediator in this pathogenetic events and its decreased 
levels are directly related to steatosis grade owing to the 
fact that adiponectin has a protective role decreasing lipid 
accumulation and fibrosis processes in liver[79]. 
Fatty free acids represent a well demonstred pathogenetic 
markers of  insulin resistance and of  its complications such 
as NAFLD owing to the fact that FFA cause liver cellular 
apoptosis and impair interplay between hepatic cells and 
immune system, cytokines, ROS and finally also impairing 
insulin production and signaling mechanisms[80-86]. 
FFA and their derivatives induce insulin resistance, 
increase liver inflammation and promote instability in 
atherosclerotic plaque by a common pathogenetic pathway 
involving Jun N-terminal kinases (JNKs) that are one of  
the mitogen-activated protein kinase (MAPK) superfamily 
as pointed out by some authors in a recent work[87]. High 
degree of  oxidative stress and its related JNK activation, as 
well as an impaired activation of  pro- and anti-apoptotic 
proteins of  the Bcl-2 family has been reported as factors 
able to contribute to hepatocyte apoptosis in a murine 
model of  non-alcoholic steatohepatitis[88]. Therefore, a direct 
role is attributed to FFAs that seem able to directly cause the 
apoptotic events by activating the proapoptotic protein Bax, 
by menas c-jun N-terminal kinase-dependent mechanisms 
as reported by a recent study conducted by Tarantino et 
al[89]. In this study authors analyzed the relationship between 
anti-apoptotic serum Bcl-2 concentrations and grade of  
steatosis and inflammation in subjects with NAFLD and 
steatohepatitis (NASH) reporting a significant predictive 
value of  Bcl-2 serum levels towards a higher frequency of  
metabolically unhealthy overweight/obese patients (MUOs) 
(obese subjects without hepatic steatosis) suggesting that 
the anti-apoptotic process could have a significant role to 
block FFA hepatotoxic actions. Although the development 
of  NAFLD has some common mechanisms with the 
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development of  metabolic syndrome, as they share the 
pathophysiologic basis of  insulin resistance, NAFLD is 
currently not a component of  the diagnostic criteria for 
metabolic syndrome. Nevertheless a recent study showed 
that ultrasonographically detected NAFLD could act as 
a possible predictive factor of  insulin resistance[90,91]. On 
this basis US-NAFLD could be used as a new criterion 
to define metabolic syndrome also in consideration of  
the high sensitivity and specificity of  abdominal US in the 
diagnosis of  NAFLD. These data have been underlined 
by Tarantino et al[91] in a recent article. In the light of  the 
various pathways thought to be central in the pathogenesis 
of  NAFLD, the main therapeutic approach consists 
in the modification of  risk factors, in particular lifestyle 
through diet and physical activity and the more promising 
pharmacological approach seems to be the use of  drugs 
able to improve insulin sensitivity such as metformin and 
PPAR (Peroxisome Proliferator Activated nuclear Receptor 
agonist). However, further studies on the pathogenesis 
of  NAFLD would be needed to identify new potential 
therapeutic targets in these patients and to define the most 
appropriate pharmacological and non-pharmacological 
therapeutic approach. Therefore, NAFLD is commonly 
associated with the metabolic syndrome which is considered 
as the hepatic expression and results from a complex 
interaction between genetic and environmental factors with 
insulin resistance as a fundamental pathogenic mechanism 
and in consideration of  the progressive increase in the 
prevalence of  insulin resistance, NAFLD/NASH should be 
considered as emerging diseases, involving a high percentage 
of  the Western population.
CONCLUSION
Diabetic foot and its related clinical conditions such as 
foot ulcers and infective complications represent the 
most common cause of  hospitalization in subjects with 
diabetes. Management of  DFS and its related treatment of  
infectious diabetic foot and amputations also represent a 
health problem in terms of  cost ( several millions of  euro 
every year). 
“The majority of  foot ulcers appear to result from 
minor trauma in the presence of  sensory neuropathy.” 
This sentence[92] underlines the critical pathogenetic triad 
of  DFS in diabetics: peripheral sensory neuropathy, 
deformity, and trauma. These risk factors have been 
reported as present in more than 60% of  diabetic foot 
complications. 
Our review aimed to underline the complex metabolic 
and inflammatory interplay that could explain high 
cardiovascular event rate of  patients with diabetic foot. 
Diabetic vascular complications recognize a well described 
inflammatory pathogenesis, but only few studies evaluated 
immune-inflammatory background of  DFS. 
Only a few previous studies[18-21] evaluated inflammatory 
markers such as cytokine and adypokines in patients with 
diabetic foot. Nevertheless several reports clearly underlined 
the role of  low serum level of  adiponectin that has been 
reported as complex metabolic and inflammatory axis 
able to predispose to atherogenesis. Adiponectin with its 
anti-inflammatory and vascular effects in is able to inhibit 
inflammatory effects of  vascular adhesion molecules and 
scavenger receptors and to lower the expression of  the 
inflammatory cytokine TNF-α, furthermore adiponectin 
enhances NO production and inhibit the proliferation and 
migration of  smooth muscle cells[93].
Findings reported by Tuttolomondo et al[21] of  low 
serum levels of  adiponectin and the significant negative 
correlation between adiponectin and several traditional 
cardiovascular risk factors in subjects with diabetic foot 
could represent a well confirmation of  this issue. Thus 
owing to the fact that several cytokines are also produced 
by adipose tissue[46] it has been hypothesized that the high 
rate of  cardiovascular events in diabetes could be due to 
a pathogenetic axis called as an “adipo-vascular” axis[44]. 
This “adipo-vascular axis” represented by low serum 
levels of  adiponectin and high serum levels of  IL-6 and 
resistin could be related to foot ulcers pathogenesis by 
microvascular and inflammatory mechanisms.
Adiponectin has been also reported by recent studies 
as involved in the regulation of  inflammatory vascular 
response by reducing the expression of  adhesion 
molecules on endothelial cells[62], impairing endothelial cell 
NF-κB-related mechanisms[45] and altering macrophage 
actions[64]. A recent research also reported how adiponectin 
inhibits the TNF-α related expression of  E-selectin, 
VCAM-1and ICAM-1 in human endothelial cells[46] thus 
indicating how adiponectin has been evaluated as real 
vasoprotective and anti-atherogenic factor . 
Recently, Ouchi et al[48] showed how low degree of  serum 
adiponectin is linked to low levels of  HDL-cholesterol, 
thus representing a real independent cardiova-scular risk 
factor, whereas high levels of  adiponectin are associated to 
a protective cardiovascular risk profile associated to high 
levels of  HDL-cholesterol. Findings by Tuttolomondo 
et al[21] of  a positive (for IL-6 and resistin) and negative 
(for adiponectin) correlation in subjects with diabetic 
foot between these immuno-inflammatory and metabolic 
markers and some clinical and laboratory variables could 
represent a further confirmation of  the crucial role of  
inflammatory and metabolic “milieu” such as cytokines 
and adipose hormones in foot complications in diabetics, 
as already reported for other vascular complications of  
diabetes.
Thus inflammation marker evaluation has in DFS 
multiple points of  potential importance concerning a 
better evaluation and analysis of  these crucial key points: 
(1) pathogenetic role in ulcers and their micro and macro-
vascular background; (2)possible link between inflammation 
state and adipo-metabolic axis; (3) predictive role towards 
foot complications such as ulcers incidence; (4) putative role 
as markers of  gravity of  wounds and ulcers in a diabetic 
foot; (5) association with cardiovascular co-morbidity 
(prevalent and incident) in subjects with DFS; (6) prognostic 
role towards ulcer healing; (7) strict association with 
peripheral artery comorbidity (PAD); and (8) pathogentic 
links with metabolic syndrome and NASH [93-99].
It explains that a strict and prospective inflammation 
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marker evaluation could be useful in practical management 
of  foot complications in diabetic subjects in every 
medical setting (Internal Medicine, Diabetology, Surgery, 
Orthopedics) to better evaluate a complex disease such as 
DFS in a multispecialistic management contest.
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